多西他赛与奥沙利铂联合治疗复发性上皮性卵巢癌疗效评价

目的 观察和评估多西他赛联合奥沙利铂方案治疗复发性上皮性卵巢癌的临床疗效及安全性.方法 对病理证实为复发性上皮性卵巢癌患者36例进行化疗.给药方案为:多西他赛75mg/m~2,静脉滴注1 h,第1天:奥沙利铂100mg/m~2,静脉滴注2h,第1天.每21 d重复,至少治疗2个周期.结果 接受治疗的36例患者均可评价疗效,完全缓解率为8.3%,部分缓解率为47.2%,总有效率55.6%.主要毒副反应为骨髓抑制和周围神经炎.结论 多西他赛联合奥沙利铂化疗方案治疗复发性上皮性卵巢癌有较好的疗效,毒副反应轻,耐受性好,值得进一步临床研究推广.

Abstract：

Objective To evaluate the efficacy and safety of docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) for treatment of recurrent epithelial ovarian cancer. Methods Thirty-six patients with histologically confirmed recurrent epithelial ovarian cancer received chemotherapy with DTX and OXA. DTX at the dose of 75 mg/m2 was administered on day 1 by intravenous infusion in 60 min, followed by OXA at 100 mg/m~2 given by a 2 h infusion. The chemotherapy cycles were repeated every 21 days, and the patients received at least 2 cycles. Results All the patients were available for response evaluation, among whom 3 (8.3%) showed complete responses and 17 (47.2%) showed partial responses, with an overall response rate of 55.6%. The main adverse effects included hematological toxicities and peripheral neuropathy. Conclusion Combination of DTX and OXA produces good therapeutic effect with tolerable toxicity profile for treatment of recurrent epithelial ovarian cancer.

Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer

Objective To evaluate the efficacy and safety of docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) for treatment of recurrent epithelial ovarian cancer. Methods Thirty-six patients with histologically confirmed recurrent epithelial ovarian cancer received chemotherapy with DTX and OXA. DTX at the dose of 75 mg/m2 was administered on day 1 by intravenous infusion in 60 min, followed by OXA at 100 mg/m~2 given by a 2 h infusion. The chemotherapy cycles were repeated every 21 days, and the patients received at least 2 cycles. Results All the patients were available for response evaluation, among whom 3 (8.3%) showed complete responses and 17 (47.2%) showed partial responses, with an overall response rate of 55.6%. The main adverse effects included hematological toxicities and peripheral neuropathy. Conclusion Combination of DTX and OXA produces good therapeutic effect with tolerable toxicity profile for treatment of recurrent epithelial ovarian cancer.